Michael Morris
MD
Medical Oncologist
👥Biography 个人简介
Michael Morris is a leading expert in advanced prostate cancer treatment and biomarker development. His research characterized AR-V7 splice variant expression as a predictor of resistance to enzalutamide and abiraterone, fundamentally altering treatment sequencing. He has led trials of PARP inhibitors in HRR-deficient prostate cancer and studied how PTEN loss affects treatment selection. His work on composite clinical trial endpoints has influenced regulatory approaches to prostate cancer drug approval.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Morris 的研究动态
Follow Michael Morris's research updates
留下邮箱，当我们发布与 Michael Morris（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment